Cannabinoid CB2 receptors in human brain inflammation
Open accessThe DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.
Abstract
The presence of functional cannabinoid CB 2 receptors in the CNS has provoked considerable controversy over the past few years. Formerly considered as an exclusively peripheral receptor, it is now accepted that it is also present in limited amounts and distinct locations in the brain of several animal species, including humans. Furthermore, the inducible nature of these receptors under neuroinflammatory conditions, in contrast to CB 1, makes them attractive targets for the development of novel therapeutic approaches. In fact, the undesired psychoactive effects caused by CB 1 activation have largely limited the clinical use of cannabinoid‐related compounds that act on these receptors. In this review some recent findings on the antiinflammatory properties of CB 2 receptors are presented, as well as new perspectives that have been obtained based on studies of human postmortem brain samples. In addition, various working hypotheses are also proposed and discussed. British Journal of Pharmacology (2008) 153, 277–285; doi:10.1038/sj.bjp.0707505; published online 15 October 2007
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global prevalence of dementia: a Delphi consensus study
Ferri, C. P., Prince, M., Brayne, C., Brodaty, H., Fratiglioni, L., Ganguli, M., Hall, K., Hasegawa, K., Hendrie, H., Huang, Y., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67889-0 · Cited by 5,332
Noseworthy, J. H., Lucchinetti, C., Rodriguez, M., & Weinshenker, B. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431307 · Cited by 2,899
International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors
Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., et al. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.161 · Cited by 2,819
Multiple Sclerosis — The Plaque and Its Pathogenesis
Frohman, E. M., Racke, M. K., & Raine, C. S. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052130 · Cited by 1,740
Identification and Functional Characterization of Brainstem Cannabinoid CB2Receptors
Van Sickle, M. D., Duncan, M., Kingsley, P. J., Mouihate, A., Urbani, P., Mackie, K., Stella, N., Makriyannis, A., Piomelli, D., Davison, J. S., et al. (2005) · Science · doi:10.1126/science.1115740 · Cited by 1,470
Inflammation in Neurodegenerative Disease—A Double-Edged Sword
Wyss-Coray, T., & Mucke, L. (2002) · Neuron · doi:10.1016/s0896-6273(02)00794-8 · Cited by 1,235 · cited 1×
“…results in a massive local accumulation of inflammatory cytokines and reactive oxygen species (‘cytokine cycle’; Mrak and Griffin, 2005) and (iv) leads ultimately to neuronal death and massive loss of functional synapses, thus dramatically altering neurotransmission (Wyss-Coray and Mucke, 2002).”
BackgroundPathways to neuronal injury and apoptosis in HIV-associated dementia
Kaul, M., Garden, G. A., & Lipton, S. A. (2001) · Nature · doi:10.1038/35073667 · Cited by 1,210
Deciphering the Molecular Basis of Memory Failure in Alzheimer's Disease
Walsh, D. M., & Selkoe, D. J. (2004) · Neuron · doi:10.1016/j.neuron.2004.09.010 · Cited by 1,207 · cited 2×
“‘amyloid hypothesis’ is now accepted (Walsh and Selkoe, 2004).”
BackgroundActivated microglia mediate neuronal cell injury via a nitric oxide mechanism
Chao, C. C., Hu, S., Molitor, T. W., Shaskan, E. G., & Peterson, P. K. (1992) · The Journal of Immunology · doi:10.4049/jimmunol.149.8.2736 · Cited by 1,136
González-Scarano, F., & Martín-García, J. (2005) · Nature Reviews Immunology · doi:10.1038/nri1527 · Cited by 1,097
Cited by
Is lipid signaling through cannabinoid 2 receptors part of a protective system?
Pacher, P., & Mechoulam, R. (2011) · Progress in Lipid Research · doi:10.1016/j.plipres.2011.01.001 · Cited by 414
Modulating the endocannabinoid system in human health and disease – successes and failures
Pacher, P., & Kunos, G. (2013) · The FEBS Journal · doi:10.1111/febs.12260 · Cited by 405
A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease
Hampel, H., Caraci, F., Cuello, A. C., Caruso, G., Nisticò, R., Corbo, M., Baldacci, F., Toschi, N., Garaci, F., Chiesa, P. A., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00456 · Cited by 360
Lipid G Protein-coupled Receptor Ligand Identification Using β-Arrestin PathHunter™ Assay
Yin, H., Chu, A., Li, W., Wang, B., Shelton, F., Otero, F., Nguyen, D. G., Caldwell, J. S., & Chen, Y. A. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m806516200 · Cited by 311
Rosenberg, E. C., Tsien, R. W., Whalley, B. J., & Devinsky, O. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0375-5 · Cited by 276
Hill, M. N., & McEwen, B. S. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2009.11.001 · Cited by 235
“While the CB2 receptor is located predominantly in peripheral immune cells and organs (Munro et al., 1993), CB2 receptors are also expressed by microglial cells in injured, infected or inflamed CNS tissue (Benito et al., 2008).”
BackgroundPolyunsaturated fatty acids, neuroinflammation and well being
Layé, S. (2010) · Prostaglandins, Leukotrienes and Essential Fatty Acids (PLEFA) · doi:10.1016/j.plefa.2010.02.006 · Cited by 167
Hsieh, G. C., Pai, M., Chandran, P., Hooker, B. A., Zhu, C. Z., Salyers, A. K., Wensink, E. J., Zhan, C., Carroll, W. A., Dart, M. J., et al. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01046.x · Cited by 139
Tracking neuroinflammation in Alzheimer’s disease: the role of positron emission tomography imaging
Zimmer, E. R., Leuzy, A., Benedet, A. L., Breitner, J., Gauthier, S., & Rosa-Neto, P. (2014) · Journal of Neuroinflammation · doi:10.1186/1742-2094-11-120 · Cited by 121
“Recent studies, however, have demonstrated microglial overexpression of CB2 in AD following Aβ deposition [88,89].”
BackgroundCocaine abuse and effects in the serum levels of cytokines IL-6 and IL-10
Moreira, F. P., Medeiros, J. R. C., Lhullier, A. C., Souza, L. D. D. M., Jansen, K., Portela, L. V., Lara, D. R., Silva, R. A. D., Wiener, C. D., & Oses, J. P. (2016) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2015.11.024 · Cited by 92
Kamila, P., Kar, K., Chowdhury, S., Chakraborty, P., Dutta, R., S, S., Singh S, A., & Prajapati, B. G. (2025) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2025.05.005 · Cited by 90
“However, reactive neuroglia associated with multiple sclerosis, HIV encephalitis, Hun-tington ’ s disease, and Alzheimer ’ s disease (AD) express elevated levels of CB2 receptors (Benito et al., 2008).”
Merighi, S., Gessi, S., Varani, K., Fazzi, D., Mirandola, P., & Borea, P. A. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.01948.x · Cited by 79
“In particular, the activation of CB2 receptors expressed in brain microglia during neuroinflammation (Benito et al., 2008; Atwood and Mackie, 2010) reduced NO production and TNF-a in primary microglia (Ehrhart et al., 2005; Merighi et al., 2012).”
BackgroundCannabinoids: new promising agents in the treatment of neurological diseases.
Giacoppo, S., Mandolino, G., Galuppo, M., Bramanti, P., & Mazzon, E. (2014) · Molecules · doi:10.3390/molecules191118781 · Cited by 79
Argue, K. J., VanRyzin, J. W., Falvo, D. J., Whitaker, A. R., Yu, S. J., & McCarthy, M. M. (2017) · eneuro · doi:10.1523/eneuro.0344-16.2017 · Cited by 47
“Initial reports limited CB2R expression to microglia, the immune cells of the brain, or astrocytes, with expression on neurons still reserved only for CB1R (Núñez et al., 2004; Maresz et al., 2005; Benito et al., 2008; Racz et al., 2008a, 2008b).”
Background
Metadata
- Authors
- Benito, C., Tolón, R. M., Pazos, M. R., Núñez, E., Castillo, A. I., & Romero, J.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2008-01
- Volume
- 153
- Issue
- 2
- Pages
- 277-285
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2018810438
- Cited by
- 291
- References
- 90
- FWCI
- 5.48
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.